People in that age group, suffering from one or more co-morbidities like heart disorders, chronic pulmonary and kidney diseases, cancer, transplant patients, uncontrolled diabetes, those on immune medications and morbid obesity conditions are eligible for
The amount people would need to pay for COVID-19 vaccination in private hospitals will be decided by the health ministry within 3-4 days, Javadekar said
India has 7,684 variants of COVID-19 virus, says study
The findings of the study become significant as in many parts of the world, mutant variants of the virus are causing a new surge in COVID-19 cases. The current increase in the number of infections in some Indian states may also be due to the presence of virus variants, it is feared
Joe C Mathew | February 23, 2021 | Updated 10:40 IST
COVID-19 in India: Study finds country may have over 7,000 variants
Indian researchers have identified 7,684 variants in SARS-CoV-2 (novel coronavirus) genomes from samples collected within the country. A recently published research paper analysing the viral variants has also listed out the top 61 non-synonymous Indian variants with details of the genomic mutation and the corresponding amino acid change in the associated viral protein.
Over 1.22 lakh beneficiaries were administered the first dose of COVID-19 vaccine in a single-day in Rajasthan on Wednesday. Heath Secretary Siddharth Mahajan said that 1,22,030 frontline workers and 337 health workers got the jabs on Wednesday.
Kochi firm PNB Vesper Life completes Phase 2 clinical trial of COVID-19 drug
The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support
PTI | February 22, 2021 | Updated 17:13 IST
The city-based PNB Vesper Life Sciences has successfully completed phase 2 clinical trials of PNB-001 (GPP-Baladol), its proprietary drug to treat the coronavirus infection and said it will soon move the government for deploying the drug for emergency use.
The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support.